Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma

Abstract

In this commentary on Wang, Wu, Xia, and colleagues, Clinical Translational Medicine, 2022, we sum up and discuss recent evidence on the regulation and relevance of the transcription factor c-FOS in diffuse large B cell lymphoma cells that are treated with epigenetic erasers of the histone deacetylase inhibitor family.

Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes

“…For example, functional dysregulation of histone acetyltransferases has been associated with cancer development, including B-cell [45,46] and T-cell lymphomas [47,48]. In humans, histone modifier gene mutations have been associated with inferior progression-free survival time in patients with T-cell lymphomas [48], and it has been demonstrated that HDAC regulates the expression of BCL6, involved in cell survival and/or differentiation in B-cell lymphoma [49], and HDAC inhibitors have been tried as therapy in humans [50][51][52]. In CML, repression of p16 tumour suppressor gene is regulated by histone H3 acetylation in vitro [53].…”

Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer

“…Truly, other targets of HDACi might also dictate resistance. For example, a recent study using single-cell sequencing illustrates that c-FOS antagonizes HDACi-induced apoptosis and is upregulated in DLBCL cells surviving HDACi (Kr€ amer and Schneider, 2022;Wang et al, 2022).…”